EDEC 2012 Congress Book Final by MCI TangenC

3rd EMIRATES DIABETES & ENDOCRINE CONGRESS 11th - 13th October, 2012 Grand Hyatt Conference & Convention Centre, Dubai, United Arab Emirates

Organised by

In Support with

www.edec-uae.com

3rd Emirates Diabetes & Endocrine Congress 2012

His Highness Sheikh Khalifa Bin Zayed Al Nahyan President of the U.A.E

3rd Emirates Diabetes & Endocrine Congress 2012

His Highness Sheikh Mohammed Bin Rashid Al Maktoum Vice President, Prime Minister and Ruler of Dubai

3rd Emirates Diabetes & Endocrine Congress 2012

His Highness Sheikh Hamdan Bin Rashid Al Maktoum Deputy Ruler of Dubai, Minister of Finance, UAE President of Dubai Health Authority

3rd Emirates Diabetes & Endocrine Congress 2012

Table of Contents Welcome Message .............................................. 10 Committees ......................................................... 11 Invited Faculty ..................................................... 12-13 General Information .............................................. 14-15 Conference Venue Map Locator ........................... 16-17 Exhibition Layout................................................... 18 Sceintific Program ................................................. 19-22 Faculty Profiles ...................................................... 23-33 Abstracts ............................................................... 34-44 Sponsors ................................................................ 45-52 Experience Dubai ................................................... 53-56 Acknowledgement .................................................. 57

3rd Emirates Diabetes & Endocrine Congress 2012

Welcome Message

Dear Participants, I would like to personally welcome you back to The 3rd Emirates Endocrine and Diabetes Congress 2012, created and organised by the Emirates Diabetes Society. Last year, this time, we were all busy gearing up for the first International Diabetes Federation (IDF) in the Middle East and North Africa region. As hosts, we had great expectations with regards to the outcome of the scientific content, participation and the impact the congress would have in the Region. We can proudly state that our team and the congress over delivered on the promises and the impact was truly astounding! As quoted by Sir Michael Hirst, IDF President Elect, in the April 2012 issue (vol:57) of the Diabetes Voice; “Dubai’s promotional tagline, ‘The Meeting Place of the World’, rang true when more than 15,000 participants gathered in Dubai for the World Congress, making it the most successful Congress ever organized by the IDF.” While we can rest on our laurels as a city, forging ahead, the burden of the disease is heavier; the challenge more complex and bigger; and the need to address Diabetes and Endocrine Diseases ever more urgent. As the Congress President, I have a vision, i.e. reduce the burden of the disease across our region. We are united in our stance, and the foundation of this vision lies where we left-off in 2009 & 2010, i.e. education and knowledge sharing. These fundamentals are the corner stones to build, what I consider the front-line force to manage and control this disease. With this as the premise, EDC’s scientific committee have put together a list of expert speakers, both from international and regional communities, to address a number of key areas that would help develop and articulate strategies and protocols that would be beneficial at a regional, national and local level. The 2012-Congress’s theme “Exploring the Shift in the Paradigm of Endocrinology and Diabetes in the Middle East” will focus on vital and relevant topics concerning our patients in the region and run parallel sessions which will include hands-on courses and workshops designed to build capacity. I encourage all of you to participate actively in our various sessions and also use this opportunity to network with peers and do enjoy your time here at the Grand Hyatt and Dubai. I look forward to meeting you all over the next few days and wish you all the very best. My best personal regards

Dr Abdulrazzaq Ali Al Madani Congress President

3rd Emirates Diabetes & Endocrine Congress 2012

Committees Organizing Committee

Dr Abdulrazzaq Ali Al Madani Chief Executive Officer (CEO) Dubai Hospital-DHA United Arab Emirates

Dr Fatheya Al Awadi Head of Medical Dept & Endocrinology Section Dubai Hospital United Arab Emirates

Dr Iyad Ksseiry Consultant Endocrinologist Head of Internal Medicine The City Hospital United Arab Emirates

Scientific Committee

Dr Bashar Afandi Member

Dr Elham Alamiri Member

Dr Ali Baqer Member

Dr Salem Arifi Beshyah Member

Dr Ahmed Hassoun Member

Dr Khaled Al Jaberi Member

Dr Jumaa Al Kaabi Member

Dr Ali Khalil Member

Dr Hussain Al Saadi Member 3rd Emirates Diabetes & Endocrine Congress 2012

Invited Faculty

Donald Coustan USA

Bernadette Biondi Italy

Mark Evans UK

Rainer D端esing Germany

Alan Garber USA

Anders Frid Sweden

Om P. Ganda USA

Rubina Heptulla USA

3rd Emirates Diabetes & Endocrine Congress 2012

Ralph Defronzo USA

Maximimilian Von Eynatten USA

Luk Van Gaal Belgium

David Matthews UK

Invited Faculty

Rayaz A Malik USA

Philip Schauer USA

Jean Claude Mbanya Cameroon

Farid Saad Germany

Wolfgang Schmidt Germany

Margaret Wierman USA

Pre-Congress Ultrasound Workshop Speakers

Murat Faik Erdogan Turkey

Alptekin Gursoy Turkey

3rd Emirates Diabetes & Endocrine Congress 2012

General Information Badges: Name badges must be visible and used at all times, throughout the conference venue, and off- site social activities. Colors: Description:

Committee (all access) Delegate (all access, except speaker preview room) Exhibitor (no access to scientific sessions) Faculty (all access) Organiser (all access) Media/Press (all access)

CME Certification: This congress is accredited by Dubai Health Authority (DHA) for 14 CME Hrs and from UAE University for 14 CME Hrs. Certificates will be issued against receipt of feedback forms on 13th October from the Registration Desk, after 13:00 pm onwards. Conference Bags: Conference bags will be distributed to registered participants at the Registration Desk (The Conference Bag is not included for students). Speaker Registration: Committee and Speaker registration and badge collection can be done in the VIP Al Majlis Room (Speakers’ Preview Room) located on the lower level. Speakers’ Preview Room: All speakers are requested to report to the Speakers’ Preview Room (VIP Majlis) at least two hours before their session, for a final check on presentation material. The Speakers’ Preview Room is available for speaker’s convenience throughout the congress for final run-throughs of their presentation. Internet: WIFI access is available throughout the venue for surfing the net. The internet vouchers can be purchased directly from the Hotel’s business centre (located in the boulevard between the convention centre and Hotel lobby). Food & Beverage: Coffee breaks and lunch boxes will be provided to registered delegates. The hotel also offers a variety of all-day dining restaurants to choose from. Automatic Teller Machines (ATM): An ATM dispenser is located at the Atrium Level of the Grand Hyatt Hotel, near the Panini Restaurant. Exhibition: The Emirates Diabetes & Endocrine Congress 2012 Exhibition is located in the Al Ameera Ballrooms. Rules: Smoking Policy- the Grand Hyatt Convention Centre is a non-smoking venue. Participants are requested to exit the building when smoking is desired, to the designated smoking corners.

3rd Emirates Diabetes & Endocrine Congress 2012

General Information Mobile Phones- Delegates are kindly requested to keep their mobile phones in the off mode in meeting rooms when scientific sessions are in progress. Parking: 24 hours courtesy valet parking is available at the congress venue. Prayer Room Prayer rooms are available for ladies and gents at the venue. Congress Secretariat: MCI - Dubai Office P.O. Box 124752 Dubai, United Arab Emirates Phone: +971 (0)4 311 6300 Fax: +971 (0)4 311 6301 edec@mci-group.com Evacuation Assembly Point: In case of an emergency evacuation procedure, please proceed in an orderly fashion to the open parking area in front of the Convention Centre. Please follow the instructions of the Hotel Staff Wardens at all times.

3rd Emirates Diabetes & Endocrine Congress 2012

BUSINESS CENTRE REGISTRATION DESK

AL REMAL

AL AMEERA BALLROOM 1, 2 & 3

SPEAKER PREVIEW ROOM

esk

ation D

Registr

Mens Pr ayer Room

LOWER LEVEL

RA 1

AL AMEE

IYA

BAN

YER

S F O

ET IN (Ba G RO niya O s 2) M

ER P VI RE P Ma VIEW jlis RO K EA

3rd Emirates Diabetes & Endocrine Congress 2012 SP

BANIYAS BALLROOM 1, 2 & 3

LEGEND

RA 3

AL AMEE

RA 2 AL AMEE

ETI NG (Ba niya ROOM s 1)

WO R (Ba KSH OP niy as 3)

Conference Venue Map Locator

AL MURJAN

AL KHALEEJ

AL ITEFAQ

AL MAASA

AL DAR

AL DANA

LEGEND

UPPER LEVEL

Conference Venue Map Locator

3rd Emirates Diabetes & Endocrine Congress 2012

Exhibition Layout

3rd Emirates Diabetes & Endocrine Congress 2012

Scientific Program

Pre-Congress Ultrasound Workshop Wednesday, October 10, 2012 08:00-09:00 Registration & Welcome Coffee

Foyer

09:00-15:30 Workshop on Thyroid Ultrasound

Al Ameera 1

EDEC 2012 Congress Program Thursday, October 11, 2012 - Day 1 08:00-09:00 Registration & Welcome Coffee

Foyer

09:00-09:30 Introduction & Opening Remarks:

Congress Chair: Fatheya Al Awadi, Dubai Hospital, UAE Scientific Committee Chair: Iyad Ksseiry, the City Hospital, Dubai, UAE

09:30-10:00

Al Baniyas 1&2

Opening Ceremony

Session I – The Role of Guidelines in the Management of Diabetes 10:00-10:30 Review of Current IDF Guidelines

Jean Claude Mbanya, University of Yaoundé I, Cameroon & Consultant Physician, Cameroon

10:30-11:00 Should Metformin be the First of Therapy in Diabetes? Alan Garber, Baylor College of Medicine, USA

11:00-11:30 Translating Diabetes Guidelines into Practice

Al Baniyas 1&2

Om P. Ganda, Harvard Medical School, USA

11:30-12:00 UAE Perspective on Diabetes Management

Abdulrazzaq Ali Al Madani, Dubai Hospital-DHA, UAE

12:00-12:15 Discussion Al Ameera/ Al Baniyas 3

12:15-13:30 Opening of Exhibition / Lunch Graduation Ceremony – Postgraduate Certificate in Diabetes Leicester University

Al Baniyas 1&2

Session II - New Therapies for Diabetes Mellitus 13:30-14:05 Impact of New Diabetes Therapies: SGLT-2 and Its Inhibitors in Type 2 Diabetes Luc Van Gaal, Antwerp University Hospital, Belgium

Al Baniyas 1&2

3rd Emirates Diabetes & Endocrine Congress 2012

Scientific Program 14:05-14:40 The Role of GLP-1 and GLP-1 Agonists in Type 2 Diabetes Wolfgang Schmidt, Ruhr-University of Bochum School of Medicine Germany

14:40-15:15 DPP-4 Inhibitors in Type 2 Diabetes

Al Baniyas 1&2

Mark Evans, University of Cambridge, UK

15:15-15:30 Discussion 15:30-16:00 Coffee Break

Al Ameera

Simultaneous MTP Sessions 16:00-17:00 Hyperprolactinemia and Pituitary Tumors

Margaret Wierman, University of Colorado School of Medicine, USA

Al Baniyas 3

Potential for Cardiovascular Benefits of Incretin Based Therapies Al Baniyas 1 & 2 Om P. Ganda, Harvard Medical School, USA

Diagnosis and Treatment of Testosterone Deficiency

Al Remal

Insulin Injection Techniques

Al Dana

Farid Saad, Germany

Anders Frid, University Hospital SUS, Sweden

Friday, October 12, 2012- Day 2 08:00-09:00 Registration & Welcome Coffee

Foyer

Session III Emerging Concepts 09:00-09:30 Advances in Management of Osteoporosis

Margaret Wierman University of Colorado School of Medicine, USA

09:30-10:00 Could Testosterone Play a Role in Prevention and Treatment of Type 2 Diabetes in Hypogonadal Men?

Al Baniyas 1&2

Farid Saad, Germany

10:00-10:30 Sulfonylureas: From Molecular Action to Clinical Benefits David Richard Matthews, University of Oxford, UK

10:30-11:00 Coffee Break

3rd Emirates Diabetes & Endocrine Congress 2012

Al Ameera

Scientific Program Session IV Obesity 11:00-11:30 Metabolic Consequences of Bariatric Surgery

Philip Schauer, Cleveland Clinic Bariatric and Metabolic Institute, USA

Al Baniyas 1&2

11:30-12:00 Recent and Future Drugs for Obesity

Luc Van Gaal, Antwerp University Hospital,Belgium

Al Baniyas 3

12:00-14:00 Prayer & Lunch Session V Cardiovascular Disease Risk in Diabetes 14:00-14:30 Early Glycemic Intervention and Long Term Outcomes Alan Garber, Baylor College of Medicine, USA

14:30-15:00 Targeting Blood Pressure in Diabetic Patients

Rainer Duesing, Universit채tsklinikum Bonn, Medizinische Universit채tsPoliklinik, Wilhelmstrasse Bonn, Germany

Al Baniyas 1&2

15:00-15:30 Diabetic Nephropathy: Is the Kidney the Unappreciated Heart in Type 2 Diabetes? Maximilian Von Eynatten, USA

15:30-15:45 Discussion 15:45-16:00 Coffee Break

Al Ameera

Simultaneous MTP sessions 16:00-17:00 Introduction to Pediatric Endocrinology

Rubina Heptulla, Albert Einstein College of Medicine, USA

Al Maasa

Endocrine Hypertension

Rainer Duesing Universit채tsklinikum Bonn, Medizinische Universit채tsPoliklinik, Wilhelmstrasse Bonn, Germany

Al Baniyas 3

Replacement with Thyroid Hormone

Al Baniyas 1&2

Bernadette Biondi University of Naples Federico II Medical School, Italy

Diabetes Neuropathy and Diabetic Foot

Rayaz Malik, Central Manchester Foundation Trust & University of Manchester, Core Technology Facility, USA

Al Remal

Insulin Injection Techniques

Al Dana

Individualization of Diabetes Treatment

Al Dar

Anders Frid,University Hospital SUS, Sweden David Richard Matthews, University of Oxford, UK

3rd Emirates Diabetes & Endocrine Congress 2012

Scientific Program Saturday, October 13, 2012 - Day 3 08:00-09:00 Registration & Welcome Coffee

Foyer

Session VI â&#x20AC;&#x201C; Hot Topics 09:00-09:45 Diabetes in the Young

Rubina Heptulla, Albert Einstein College of Medicine, USA

09:45-10:30 Gestational Diabetes Mellitus: Diagnosis and Management

Al Baniyas 1&2

Donald Coustan, Brown Medical School, USA

Al Ameera

10:30-11:00 Coffee Break

11:00-11:45 New Concepts in Diabetes Pathophysiology: What We Should Know

Ralph Defronzo, University of Texas Health Science Centre and the Audie L. Murphy Memorial VA Hospital, USA

11:45-12:30 Clinical Significance of Subclinical Thyroid Dysfunction.

Al Baniyas 1&2

Bernadette Biondi, University of Naples Federico II Medical School, Italy

12:30-13:00 Congress Chair Closing Remarks Distribution of CME Certificates 13:00-14:00

Al Baniyas 3

Lunch

Workshops: October 11 & 12, 2012 15:00-16:00

11th & 12th October 2012

Excellence in Diabetes care

Al Itefaq Meeting Room

16:00-17:00

11th & 12th October 2012

Diabetes Education

Al Khaleej Meeting Room

Insulin Pump Therapy

Al Murjan Meeting Room

15:00-16:00 & 12th October 2012 16:00-17:00

3rd Emirates Diabetes & Endocrine Congress 2012

Faculty Profiles

Bernadette Biondi Italy

Dr. Bernadette Biondi is Professor of Endocrinology at the Endocrine Division of the Department of Molecular and Clinical Endocrinology and Oncology of the University of Naples Federico II Medical School, Naples, Italy. She is tutorial teacher in Endocrinology and Cardiovascular Endocrinology for the students of University of Naples Medical School. Dr.Biondiâ&#x20AC;&#x2122;s clinical research has focused on the cardiovascular effects of thyroid hormone, subclinical thyroid disease and clinical outcomes in patients with thyroid cancer. She is the author or co-author of numerous papers that appeared in such journals as Journal of Clinical Endocrinology and Metabolism, European Journal of Endocrinology, Annals of Internal Medicine, Circulation, Nature Clinical Practice in Endocrinology and Metabolism, New England Journal of Medicine etc, Endocrine Review, JAMA, The Lancet.

Donald Coustan USA

Donald R. Coustan, MD is former Obstetrician & Gynecologist-in-Chief, Women & Infants Hospital of Rhode Island, and former Chace/Joukowsky Professor and Chairman, Department of Ob/Gyn, Warren Alpert Medical School of Brown University. He is currently Professor of Obstetrics and Gynecology and attending physician in Maternal-Fetal Medicine at the above institutions. He graduated from Yale Medical School in 1968, and did his internship in Internal Medicine and residency in Obstetrics and Gynecology at Yale-New Haven Medical Center. After two years in the Navy, he returned to Yale in 1975. He moved to Brown and Women & Infants Hospital in 1982. In 1991 became Chair of the Department of Obstetrics and Gynecology at Brown. He stepped down from the chair in 2008. Dr.Coustan has published widely in the areas of diabetes and pregnancy and gestational diabetes. He is Regional Director for North America of the HAPO study. Dr.Coustan has served as President of the Rhode Island Medical Society, and of the Society for Maternal-Fetal Medicine. He has served on the Board of Directors of the American Diabetes Association, and on the National Advisory Committee of the Robert Wood Johnson Clinical Scholars Program.

3rd Emirates Diabetes & Endocrine Congress 2012

Faculty Profiles

Ralph Defronzo USA

Ralph A. DeFronzo, MD, is Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Audie L. Murphy Memorial VA Hospital in San Antonio, Texas. Dr.DeFronzo is a graduate of Harvard Medical School and did his training in Internal Medicine at the Johns Hopkins Hospital. He completed fellowships in endocrinology at the National Institutes of Health and Baltimore City Hospitals and in Nephrology at the Hospital of the University of Pennsylvania. Subsequently, he joined the faculty at the Yale University School of Medicine (1975-88) as an Assistant/Associate Professor. His major interests focus on the pathogenesis and treatment of type 2 diabetes mellitus and the central role of insulin resistance in the metabolic-cardiovascular cluster of disorders known collectively as the Insulin Resistance Syndrome. Using the euglycemic insulin clamp technique incombination with radioisotope turnover methodology, limb catheterization, indirect calorimetry, and muscle biopsy, Dr.DeFronzo has helped to define the biochemical and molecular disturbances responsible for insulin resistance in type 2 diabetes mellitus. For his work in this area, Dr.DeFronzo received the prestigious Lilly Award (1987) by the American Diabetes Association (ADA), the Banting Lectureship (1988) by the Canadian Diabetes Association, the Novartis Award (2003) for outstanding clinical investigation world wide and many other national and international awards. He also is the recipient of the ADA’s Albert Renold Award (2002) for lifetime commitment to the training of young diabetes investigators, the Italian Diabetes Society Mentor Award (2008), the ADA’s Banting Medal for Scientific Achievement (2008), the EADS’s Claude Bernard Lecture (2008), and the Philip Bandy Lecture (2008). With more than 500 articles published in peer-reviewed medical journals, Dr. DeFronzo is a distinguished clinician, teacher, and investigator who has been an invited speaker at major national and international conferences on diabetes mellitus.

Rainer Duesing Germany

Rainer Duesing studied medicine at the Universities of Bonn and Würzburg, Germany. After receiving his medical license, he was an Associate Research Professor at the State University of New York Medical School at Buffalo, New York and a Visiting Associate Professor at the National Institutes of Health, National Heart, Lung, and Blood Institute, the HypertensionEndocrine Branch in Bethesda, Maryland. After returning to Germany he became a Professor of Internal Medicine at the University of Bonn where his present responsibility is heading the Hypertension Clinic and the Department of General Internal Medicine. He has published over 330 papers predominantly in the field of hypertension. Professor Düsing is a member of several German and American professional and scientific societies and organizations, including the German and American Societies of Hypertension. He has been a member of the executive council of the German Hypertension Society and a fellow of the American Heart Association. Furthermore, he served on the Editorial Board of the Journal of Hypertension and is a Clinical Hypertension Specialist of the European and German Societies of Hypertension.

3rd Emirates Diabetes & Endocrine Congress 2012

Faculty Profiles

Marc Evans UK

Marc Evans has been a Consultant Diabetologist at Llandough Hospital and the University Hospital of Wales since the beginning of 2003. He was previously a Lecturer in Diabetes and Endocrinology at the University of Wales College of Medicine. Dr Evans has a continuing interest in education and is regularly involved in post-graduate education in the field of diabetes, lipid metabolism and cardiovascular disease. As a clinical lecturer Dr Evans developed various clinical and laboratory based studies to evaluate the potential vascular benefits of the insulin sensitizers. He successfully developed a specialised cardiovascular risk factor and metabolic syndrome assessment clinic service. In addition he developed a specialist nurse led metabolic review clinic for patients with type 2 diabetes. He has published over 75 articles, book chapters and abstracts.

Maximimilian Von Eynatten USA

Medical Education: 1994-1997: University of Ulm, Medical School 1997-2001: University of Heidelberg, Medical School MD Thesis: Lipoprotein Lipase May Link Adiponectin with Dyslipidemia and Atherosclerosis (Dep. Endocrinology & Metabolism; University of Heidelberg) PhD Thesis (Habilitation): Adipokines in the Diagnosis and Prevention of Cardiometabolic Disorders (Dep. Nephrology, University of Munich) Clinical and Scientific Assignments: 06/2001 - 09/2005 Scientific Resident at the University Hospital Heidelberg (Dep. Endocrinology & Metabolism) 10/2005 - 09/2006 Scientific Resident at the University Hospital Wuerzburg (Dep. Endocrinology & Metabolism) 10/2006 â&#x20AC;&#x201C; 05/2009 Scientific Resident at the University Hospital Munich, Klinikum rechts der Isar (Dep. Nephrology) 06/2009 â&#x20AC;&#x201C; 03/2011 Global Senior Medical Director Diabetes, Boehringer Ingelheim, Ingelheim, Germany Since 04/2011 Executive Director Metabolic Diseases, Boehringer Ingelheim Pharmaceutical Inc, Ridgefield, CT, USA 3rd Emirates Diabetes & Endocrine Congress 2012

Faculty Profiles Qualifications: 05/2001 Board Certification in General Medicine 04/2008 Board Certification in Internal Medicine 08/2008 Diabetology (DDG) 04/2009 Hypertensiology (DHL) 04/2010 Assistant Professor for Medicine, Munich University 11/2010 Board Certification in Nephrology Member of Associations: American Diabetes Association (ADA) American Association of Clinical Endocrinologists (AACE) European Association for the Study of Diabetes (EASD) Deutsche Diabetes Gesellschaft (DDG) Bund Deutscher Internisten (BDI) Ridgefield, September 2012

Anders Frid Sweden

Graduated from Medical School June 1977, Specialist in Internal Medicine January 1985 Thesis for the degree of Dr. Med. Sc. (Ph D) march 1992 at Karolinska Institute of Stockholm: Insulin Injection and Absorption. Since october 2001 senior consultant at Clinic of Endocrinology, University Hospital SUS, Malmö, Sweden. Investigator in over 20 clinical trials. Medical supervisor for the Diabetes Nurse education at University of Malmö. Member of the Advisory Board for the Rashid Center for Diabetes and Research in Ajman, United Arab Emirates. Member of the Internationl Scientific Advisory Board, Becton Dickinson. Member of Global Device Advisory Board, Eli Lilly. Has published over 50 papers mainly in the areas of insulin injection technique, diabetes and pregnancy and diet and diabetes.

Luk Van Gaal Belgium

Luc Van Gaal studied medicine at the University of Antwerp, where he graduated in 1978. He obtained a specialist degree in internal medicine and afterwards in endocrinology and metabolism in 1983. Since then, he has become responsible for the Metabolic Unit at the University Hospital Antwerp. In 1992 he became Professor of Medicine at Antwerp University and is currently head of the department of Endocrinology, Diabetology and Metabolism of the University Hospital. Professor Van Gaal’s main clinical and research interests are related to obesity, type 2 diabetes and lipid metabolism. He is a member of many scientific, national and international societies and a member of the Editorial Board of a series of scientific journals. He is board member 26

3rd Emirates Diabetes & Endocrine Congress 2012

Faculty Profiles of the Belgian Association for the Study of Obesity (BASO) and Past-President of the Belgian Diabetic Society. He is as a founding member also involved in the scientific activities of the Obesitas Forum (Belgium) and the International (IASO) SCOPE programme. He is the running secretary of the Belgian Endocrine Society. In 2000, he was the co-President of the 10th European Congress on Obesity, organized in Antwerp in May 2000. He has published more than 220 papers in international medical journals, mainly in the areas of general endocrinology, obesity, diabetes and lipids and has contributed to a number of textbooks about obesity.

Alan Garber USA

Dr. Alan Garber is a professor of medicine, biochemistry and molecular biology, and molecular and cellular biology in the Division of Diabetes, Endocrinology and Metabolism at the Baylor College of Medicine in Houston, Texas. He has served on the boards of numerous professional organizations including the American Association of Clinical Endocrinologists, for which he is currently president elect, the American Diabetes Association (past president, Texas Affiliate), and the Southern Society for Clinical Investigation (past president). In addition, he has chaired several diabetes guideline writing committees, including that of the AACE/ACE Consensus Statement on Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia. Dr. Garber has authored approximately 275 peer-reviewed publications, as well as book chapters and monographs on diabetes and its complications, and is currently the chief medical editor of Endocrine Today and editor of Diabetes, Obesity and Metabolism.

Om P. Ganda USA

Dr.Ganda is a Senior Physician, and Director of the Lipid Clinic at the Joslin Diabetes Center, and Associate Clinical Professor of medicine at the Harvard Medical School in Boston, Massachusetts. Dr Ganda has been a co-investigator for several National Institutes of Health (NIH) studies, including the Diabetes Control and Complications Trial (DCCT) and the Diabetes Prevention Program (DPP). He is currently a co-investigator for the NIH Epidemiology of Diabetes Interventions and Complications (EDIC) study. He is also participating in clinical trials related to lipid-lowering drugs and diabetes management. Dr.Ganda has authored more than 120 publications including 45 original articles, 40 review articles, and 25 book chapters. Dr.Ganda is an associate editor of Endocrine Practice, and serves on the editorial board of Diabetes Research and Clinical Practice . He is an ad hoc reviewer for several journals including Diabetes, Diabetes Care, Diabetologia, The Journal of Clinical Endocrinology and Metabolism, JAMA, and The New England Journal of Medicine. He is an invited reviewer for the scientific abstracts for the annual ADA meetings. Dr.Ganda received his MBBS degree from S.M.S. Medical College at the University of Rajasthan in India. He completed a residency in medicine at the All India Institute of Medical Science in New Delhi and at the Tufts University School of Medicine in Boston. Dr.Ganda completed a clinical fellowship in endocrinology and metabolism at the Boston VA Hospital and Tufts 3rd Emirates Diabetes & Endocrine Congress 2012

Faculty Profiles University School of Medicine and a research fellowship in medicine at the Joslin Diabetes Center and the Brigham and Women’s Hospital at Harvard Medical School. Dr Ganda’s awards and honors include Capp’s Research Scholar Award from Harvard Medical School, RV Sathe Oration Award at the Golden Jubilee of the Association of Physicians of India (API, 1995); GP Moses Oration, Research Society for the Study of Diabetes( RSSDI, 2000); and the M. Viswanathan Oration Award at the Research Society for the Study of Diabetes in India (RSSDI, 2003). Dr Ganda serves as a Commissioner on the Asian American Commission of Massachusetts.

Rubina Heptulla, MD USA

The doctor is Professor of Pediatrics and Medicine at The Children’s Hospital at Montefiore and Albert Einstein College of Medicine in the Bronx, New York. She is also the Division Chief of Pediatric Endocrinology and Diabetes. The doctor received her medical degree from University of Delhi in 1990. She completed her clinical pediatrics residency training at Hasbro Children’s Hospital, RI and Tufts University. She then did a fellowship in Pediatric Endocrinology at Yale University. She then took a position at Baystate Medical Center for a period of 2 years as Assistant Professor of Pediatrics. After which she was recruited to Baylor College of Medicine in Houston, TX for a period of 10 years where she is established a state-of-the-art pediatric diabetes research program working both in the area of pediatric type 1 and 2 diabetes. Dr. Heptulla is the recipient of many research awards and grants. She was the recipient of the Clinical Scholar award from the Pediatric Endocrine Society. She has received the JDRF award and the CHRC awards for her research. She is the recipient of the prestigious McNair Scholar award for juvenile diabetes from the Robert and Janice McNair Foundation. She rose in ranks at Baylor receiving a tenured Associate Professorship with an endowment from the McNair Foundation and was fully funded by the National Institute of Health for her research. In 2009, Dr. Heptulla was recruited to lead the division of Pediatric Endocrinology and Diabetes at the Albert Einstein College of Medicine and The Children’s Hospital at Montefiore. In this new position Dr. Heptulla has set up a NIH funded research program for children with type 1 diabetes using new medications and “the artificial pancreas” project was started at Einstein. Her research spans many areas including depression in diabetes, problems with adherence and the role of meal related high sugars. The doctor has written over 40 articles, book chapters, and reviews on diabetes in children.

David Richard Matthews UK

Dr Matthews currently holds the following positions: He is a Professor of Diabetic Medicine, Nuffield Department of Clinical Medicine, University of Oxford; Tutorial and Governing Fellow of Harris Manchester College, Oxford; Vice Principal, Harris Manchester College, Oxford; Co-Director of the UK Diabetes Research Network; NIHR Senior Investigator; Director of the Oxford Health Alliance and Emeritus Founding Chairman, OCDEM. He has received his Accreditation and GMC in 1984 from the Royal College of Physicians: 28

3rd Emirates Diabetes & Endocrine Congress 2012

Faculty Profiles Accreditation in Medicine, Endocrinology and Diabetes GMC: 2223940 Dr Matthews has also received numerous Academic awards (all awarded in open competition), the most recent being in 2011, “University Sermon - Jesus College - “Mathematics, medicine and mercy” (The Ramsden Sermon). Currently he holds other appointments as well as listed below: Hon Consultant Physician, Oxford Radcliffe Hospitals; Founding Trustee and Director, Oxford Health Alliance (OxHA); EASD Council member; EASD Chairman of Panel on Global Statements; Co-chairman of the CANVAS trial; Editorial Board, Diabetic Medicine; Editorial Board, European Journal of Clinical Pharmacology; Editorial Board, Diabetes & Vascular Disease Research; Lay Preacher, Methodist Church; Chairman, Methodist Relief and Development Fund

Jean Claude Mbanya Cameroon

Professor Jean Claude Mbanya is President of the International Diabetes Federation (IDF). He is Professor of Medicine and Endocrinology at the Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Cameroon and Consultant Physician, Director of the Health in Transition Research Group, Director of the National Obesity Centre University of Yaounde, Cameroon and Chief of the Endocrinology and Metabolic Diseases Unit at the Hospital Central in Yaoundé. He was instrumental in the IDF-led ‘Unite for Diabetes’ campaign, which led to passage of the United Nations Day Resolution on Diabetes in December 2006. He now steers IDF strategic direction to encourage governments to implement polices for the treatment, care and prevention of diabetes. Professor Mbanya’s research mainly focuses on cultural diabetesrelated factors, which are often unique to the African countries and communities he studies. His practice and research have largely contributed to increase the world’s awareness on diabetes in Africa, a continent where non-contagious diseases such as diabetes are too often overlooked. Cameroon has now become an important centre of research, acclaimed by the medical community. Professor Mbanya has been actively involved with IDF for many years, notably as President-Elect (2006-2009), Chair of the IDF African Region (1994-2000), Vice-President of IDF (2000-2006), member of the Board of Management and Executive Board (1994-present) and Chair of the IDF Task Force on Insulin, Test Strips and Other Diabetes Supplies (1997-2006). Prof Mbanya also serves on several WHO advisory groups: the WHO African Advisory Committee on Health Research and Development, the WHO Expert Advisory Panel on Chronic Degenerative Diseases Diabetes, and the WHO Committee on Classification and Diagnosis of Diabetes. Professor Mbanya has served on the editorial boards of Diabetes Voice, Practical Diabetes International, International Diabetes Digest and British Medical Journal. He is currently co-editor of Diabetes in Africa. He is a recipient of many international research grants and awards including the American Diabetes Association’s 2004 Harold Rifkin award for Distinguished International Service in the Cause of Diabetes and the 2009 Philip Sherlock Award of the University Outreach Diabetes Group, Jamaica, for his outstanding international service in the field of diabetes.

3rd Emirates Diabetes & Endocrine Congress 2012

Faculty Profiles

Farid Saad Germany

Dr Farid Saad was born in Alexandria, Egypt. He did his studies in Human and Veterinary medicine in 1973-1980. From 1990-1998 he worked as a specialist for reproductive endocrinology, pediatricendocrinology, and andrology, Ferring GmbH, Kiel, Germany, after which till about 2001 he served as a leader of clinical development andrology, Jenapharm, Jena, Germany; and specialized in endocrinology of aging, male aging, male hormonal fertility control From 2001– 2007 he served as Leader of the product group” Male Health Care“, Schering AG, Berlin, Germany and from 2007 – 2012 Head of scientific affairs Men’s Healthcare, Bayer Pharma AG, Berlin, Germany. Since April 2012 he has been appointed Head of Global Medical Affairs Andrology, Bayer Pharma AG. In the years 2005-12-28 he received the Honorary professorship in clinical research and endocrinology at Gulf Medical College, Ajman, United Arab Emirates and from 2006-08-10 the Honorary professorship at Men’s Health Reproduction Study Center, Hang Tuah University, Surabaya, Indonesia

Philip Schauer USA

Dr. Philip Schauer is Professor of Surgery at the Cleveland Clinic Lerner College of Medicine, Chief of Minimally Invasive General Surgery and Director of the Cleveland Clinic Bariatric and Metabolic Institute (BMI). He is past president of the American Society for Metabolic & Bariatric Surgery (ASMBS). He is co-chair of Obesity Week, the worlds largest annual meeting devoted to the science and treatment of Obesity starting November 2013. After receiving his medical degree from the Baylor College of Medicine, Dr. Schauer completed his residency in surgery at The University of Trans, where he served as chief resident of general surgery. He then completed his fellowship in laparoscopic surgery at Duke University Medical Center. Prior to joining The Cleveland Clinic in 2004, Dr. Schauer served as director of endoscopic surgery, director of bariatric surgery and Director of the Mark Ravitch/Leon Hirsch Center for Minimally Invasive Surgery at the University of Pittsburgh Medical Center. Dr. Schauer’s clinical interests include surgery for severe obesity, minimally invasive surgery (laparoscopic) and gastrointestinal surgery. He has performed more than 5000 operations for severe obesity. His research interests include the pathophysiology of obesity and related diseases, physiologic effects of laparosopic surgery on postoperative injury and recovery, and outcomes of laparoscopic management of obesity, gastrointestinal diseases, and hernias. He has also participated in the development of new minimally invasive, endosocopic and laparoscopic operations. New concepts in surgical training and education have been a major focus of his educational interests. He has authored more than 200 scientific papers, editorials, textbook chapters, and video productions. He is editor of the textbook Minimally Invasive Bariatric Surgery. He has been an invited speaker for more than 100 regional, national and international lectures on the subject of obesity surgery and laparoscopic surgery. Its is principal investigator of the STAMPEDE trail comparing medical and surgical treatment of diabetes and 2 NIH funded studies evaluating surgical treatment of diabetes and obesity. He is past chairman of the research and training and credentialing committees of ASMBS. He is current chairman of the Bariatric Surgery Section of the Obesity Society. He has been on 30

3rd Emirates Diabetes & Endocrine Congress 2012

Faculty Profiles the board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons. He is also a member of International Federation of Surgery for Obesity, the American Surgical Association, the Society of University Surgeons, the Society of Surgery of the Alimentary Tract, Central Surgical Society, and the Society of Clinical Surgery. He is a member of the Board of Governors of the Fellowship Council and past marlser of the American Board of Surgery Advisory Council. He is on the editorial board of Surgery for Obesity and Related Diseases and Obesity Surgery as well as 3 other medical journals. He has been director of more than 100 courses and workshops on advanced laparoscopic surgery and has trained more than 40 fellows in advanced laparoscopic and bariatric surgery.

Wolfgang Schmidt Germany

Wolfgang Schmidt is Chair and Professor of Internal Medicine at the Ruhr-University of Bochum School of Medicine and Director of the Department of Medicine at the University’s St. Josef Hospital. Professor Schmidt’s major clinical areas of expertise are wide-ranging and include gastroenterology, diabetology, hepatology, gastrointestinal (GI) endocrinology, GI oncology and general internal medicine. His major research areas are enteroinsular axis, incretins, regulatory gut brain peptides, type 2 diabetes (pathophysiology and novel therapeutic strategies), pancreatitis and GI malignancies. Professor Schmidt has published over 280 peer-reviewed articles, 30 book chapters and reviews and more than 300 abstracts. He has been the Editor-in-Chief of Regulatory Peptides for 10 years and has received 17 scientific awards and honours.

Margaret Wierman USA

Dr. Margaret E. Wierman is a Professor in Medicine and Director of the Pituitary Program at the University of Colorado School of Medicine. She is Chief of Endocrinology at the Denver VAMC. As a reproductive and neuroendocrinologist, she is clinically interested in hormonal disorders. Her basic research is in the genes that control the reproductive axis to understand disorders of pubertal development and acquired hormonal problems and pituitary tumorigenesis. Clinical research involves neuroendocrine dysfunction after traumatic brain injury. Her interest in osteoporosis involves understanding how hormones work in bone metabolism and alternative therapies to prevent fractures in patients where hormones are not an option. She is currently the Vice President, Clinical Scientist of the Endocrine Society and Chair of the Endocrine Society’s Clinical Guidelines on Androgens in Women.

3rd Emirates Diabetes & Endocrine Congress 2012

Faculty Profiles Pre-Congress Workshop Speakers

Murat Faik Erdogan Turkey

Started his medical education in Ankara University, School of Medicine in 1983.Worked on Clinical Endocrinology, in the University of Wales, with Prof. R. Hall for three months in 1986, when he was a third year medical student. Graduated from medical school and started Internal Medicine fellow-ship in 1989. Worked with Prof. Dr. Akira Arimura on molecular endocrinology, in Tulane University, United States- Japan laboratories, New Orleans, USA, for one year in 1993. Gained his speciality in Internal Medicine, in June 1995 with his thesis named ‘The importance of iodine deficiency, in the etiopathogenesis of endemic goiter in Turkey ’ Started his training in Endocrinology and Metabolism at the same University in May 1996 and finished his fellow-ship in June 1998. Became an Associate Professor in Endocrinology and Metabolism in 1998 and full Professor in 2004. Has several national and international publications in the field of Endocrinology and Metabolism. Worked as congress scientific secretary of the congresses and joint meetings organised by the Society of Endocrinology and Metabolism of Turkey between 1997 and 2001. Organizing scientific secretary of ETA 2004, Istanbul. Organized and took place in several thyroid ultrasonography courses during ETA and ITC meetings. Specific fields of interest ‘iodine deficiency’, ‘thyroid nodules’. ,‘sporadic or familial medullary thyroid cancer’ , ‘MEN 2 Syndromes’ ‘thyroid ultrasonography’. Worked with Turkish Government Ministry of Health, Mother and Child Care General Directorate since 1997, for the determination of Iodine Status and control of Iodine prophylaxis programme in Turkey and also in Turkish republic of Northern Cyprus. Organized, directed and worked himself on several iodine surveys all over the Turkey. Gave several lectures educational courses, published medical and paramedical articles, took part on several television programmes covering iodine deficiency and endemic goiter in Turkey. Worked as the National Representative of Turkey, in ICCIDD West, Central Europe Region. Executive Committee Member of ETA (European Thyroid Association)(2004-2009), Senior advisor ICCIDD (International Council for the Control of Iodine deficiency disorders, National representative ICCIDD; member AACE (American Association of Clinical Endocrinologists).

Alptekin Gursoy Turkey

AREAS OF EXPERTISE: A. 1. 2. 3. 4. 5. 6. 32

Clinical General Endocrinology Thyroid ultrasound Fine needle aspiration of thyroid nodules and other masses Management of Thyroid Nodules and Thyroid Cancer Autoimmune Thyroid Diseases Diagnosis and treatment of Diabetes and related complications

3rd Emirates Diabetes & Endocrine Congress 2012

Faculty Profiles B. Research 1. Thyroid Nodules and Thyroid Cancer 2. Ret protooncogene mutations in medullary thyroid carcinoma 3. Autoimmune Thyroid Disorders 4. Thyroid ultrasound and fine-needle aspiration biopsy CURRENT MEMBERSHIPS IN THE PROFESSIONAL ORGANIZATIONS Member, The Society of Endocrinology and Metabolism of Turkey Member, Turkish Society of Internal Medicine Member, European Society of Endocrinology Member, European Thyroid Association SCIENTIFIC PRODUCTION 60 original papers on peer reviewed Journals More than 100 national/international meeting abstracts and book chapters Many lectures in national and international meetings SPECIFIC SKILLS Neck ultrasonography, diagnostic and invasive ~ 3000 neck ultrasound examinations/year in patients with thyroid/parathyroid diseases (including thyroid cancer diagnosis and follow up) ~500 neck ultrasound-guided fine needle aspiration biopsies/year Molecular analysis of ret proto-oncogene mutations Diagnostic work-up in detection of ret proto-oncogene mutations in sporadic and hereditary medullary thyroid carcinoma

3rd Emirates Diabetes & Endocrine Congress 2012

Abstracts Session I

Thursday, October 11, 2012 - Day 1

Jean-Claude Mbanya Cameroon

Review of Current IDF Guidelines The IDF Guidelines aims to provide an updated evidence review; make globally relevant recommendations to highlight resource issues in diabetes prevention and care and provide a template which can be used by countries for local adaptation. Since the last review of the Type 2 diabetes guidelines in 2005, we have witnessed the use of HbA1c for diagnosis of diabetes, publication of community diabetes prevention programs, multi-factorial interventions and large scale clinical trials; TZDs have become less favoured and there has been the availability of new therapies including DPP-4 inhibitors and GLP-1 analogues. The current update of the IDF type 2 diabetes guidelines heralds the changing of HbA1C treatment targets and the introduction of treatment algorithms. The HbA1c treatment targets clearly advise people with diabetes that maintaining a DCCT-aligned HbA1c below 6.5% should minimize their risks of developing complications. The consideration of setting this target comes from significant outcome studies including the ACCORD, ADVANCE and VADT. But is there a threshold for glucose and complications and an absolute reduction in complications risk and numbers needed to treat (NNT)? What arsenal of drugs is available to achieve the HbA1C and the threshold for glucose and complications targets and what is the evidence of their clinical effectiveness? These questions will be answered during the presentation. As evidenced in the ADVANCE study combined intensive glucose control and blood pressure lowering produced additional reductions in clinically relevant outcomes. Indeed, the effects of blood pressure and blood glucose interventions are independent and additive. In conclusion, the evidence-base for universal tight glycaemic control is questionable; however, there are limited treatment specific outcome studies to develop evidence based treatment algorithms. IDF has developed an evidenceinformed consensus treatment algorithm with the objective to provide a template which can be adapted for local use.

Alan J Garber USA

Should Metformin be the First of Therapy in Diabetes? Metformin has achieved an unique position in the spectrum of anti-diabetes therapies. In the space of a mere 20 years, it has transformed itself from an idiosyncratic treatment only for obese diabetic patients to become the nearly universally accepted first line treatment for virtually all patients with type 2 diabetes. For many years, metformin was known to be relatively free of hypoglycemia and to have modest weight loss potential, It was not until the results of the UKPDS became available in 1998 that the actual cardiovascular benefits of this agent became apparent. In that study no other treatment within the initial 10 year treatment period had such a clear cut CHD benefit. Indeed, positive CHD reductions were only noted for other therapies after the additional 10 year extension with an average duration of follow-up of 17 years. Hypoglycemia has become increasingly important in recent years. Several studies have clearly shown that hypoglycemia, especially major episodes increase CHD events by 3 fold and increase total mortality by a similar amount. One of the most attractive features of metformin is its relative freedom from this complication of many other anti-diabetic therapies. One of the issues with metformin usage is its tolerability as well as its BID nature. One change in the formulation of the drug has greatly improved both of these issues. The use of extended release formulations of metformin has improved tolerance to the drug and reduced by half, the number of patients who discontinue the 34

3rd Emirates Diabetes & Endocrine Congress 2012

Abstracts agent. Furthermore, since the extended release agent is a once daily drug, it can be given easily with all of the patient’s other medications and thereby enhanced patient adherence to the agent..

Om P. Ganda USA

Translating Diabetes Guidelines into Practice The severity and duration of Hyperglycemia are key drivers of microvacular and neuropathic complications of diabetes, and also contribute to the cardiovascular morbidity and mortality. The DCCT and the UKPDS long- term follow-up observations have clearly established the concept of “metabolic memory” or “legacy effect”, and consequently the importance of optimal glycemic control in preventing these long- term complications. The goal of glycemic control in primary prevention is A1C < 7.0%, and even lower if feasible safely. Yet more than 50 % of patients are still not achieving glycemic, blood pressure, and lipid targets. The non- pharmacological approaches including diet and lifestyle changes are critical in preventing the progression and treatment of hyperglycemia; yet not enough for most patients with diagnosed diabetes. Guidelines for pharmacological management have evolved during the past 15 years. Metformin, unless contra-indicated, remains the initial drug for most patients soon after diagnosis. The ADA and EASD recommendations were somewhat restrictive until recently, emphasizing continued use of sulfonylurea and insulin, after metformin alone fails. However, hypoglycemia and weight gain with both of these agents have limited the optimization of control for many patients in the past. However, with the availability and safety record of several novel drugs, particularly, incretin-based agents that have certain unique features and relatively minimal adverse effects, the recent ADA/EASD consensus statement emphasizes a personalized approach. These agents are now recommended as the second- line drug, generally in combination with metformin, without the untoward effects of weight gain, hypoglycemia, and other adverse effects with traditional agents. Currently, long- term trials with newer agents to assess the cardiovascular safety are underway. Also emphasized in the ADA/ EASD and the AACE guidelines is the need for early combination therapy or initiating treatment with dual therapy, in patients with poor control and/or symptoms of hyperglycemia. Finally, the treatment goals and the choice of drugs should be tailored according to co-morbidities, and renal and liver functional status. Due to the progressive nature of the disease, insulin treatment with or without combination with other drugs, is still required for many patients with type 2 diabetes. Early initiation of basal insulin therapy, when indicated, can help prevent the progression of complications. Some patients with type 2 diabetes will require physiologically designed, practical, insulin regimens in combination with non- insulin agents of equal importance in preventing CVD in type 2 diabetes are the goals and current guidelines for lipid and blood pressure management.

3rd Emirates Diabetes & Endocrine Congress 2012

Abstracts Session II Luc Van Gaal Belgium

Impact of New Diabetes Therapies: SGLT-2 and Its Inhibitors in Type 2 Diabetes Submission Pending

Wolfgang Schmidt Germany

The Role of GLP-1 and GLP-1 Agonists in Type 2 Diabetes Submission Pending

Marc Evans UK

DPP-4 Inhibitors in Type 2 Diabetes Weight gain and hypoglycaemia are major challenges in the achievement of optimal glycaemic control in people with type 2 diabetes, limiting the potential benefits which are related to the achievement of glycaemic targets. Current guidelines recognise the utility of the incretin based therapies, both DPP-4 inhibitors and GLP-1 receptor agonists in relation to managing blood glucose in assocation with with weight and hypoglycaemia benefits. DPP-4 inhibitors utilise the incretin pathway thereby producing glucose dependent effects on both insulin and glucagon secretion. There are multiple currently available DPP-4 inhibitors with some potential pharmacological differences existing between these agents, particularly from the perspective of mechanism of DPP-4 inhibition. Considerable debate exisits around potential clinical differences between the available agents, while available safety data for the DPP-4 inhibitors class of drugs is reassuring. To make informed decisions with repsect to the initiation of a DPP-4 inhibitor as an alternative to another blood glucose agent as well as making specific choices within the class, it is essential to fully understand both the clinical and pharmacological data in relation to the DPP-4 inhibitor class.

Session III

Friday, October 12, 2012 - Day 2

Margaret Wierman USA

Advances in Management of Osteoporosis Osteoporosis is a disorder of bone fragility that increases the risk for fracture. This lecture will review the incidence and prevalence of low bone mass in women and men and will outline the risk factors for fracture in patients. In addition to discussion of nonpharmacologic interventions and optimal calcium and vitamin D regimens, we will outline the currently available treatment strategies for osteoporosis including bisphosphonates, hormone therapy, recombinant parathyroid hormone and the monoclonal antibody against the RANK ligand. Efficacy and safety issues will be reviewed. New therapies in the pipeline will be outlined. Despite the morbidity and mortality associated with fracture, only limited numbers of patients are evaluated and treated, suggesting increased awareness and intervention are needed. 36

3rd Emirates Diabetes & Endocrine Congress 2012

Abstracts Farid Saad Germany

Could Testosterone Play a Role in Prevention and Treatment of Type 2 Diabetes in Hypogonadal Men? Obesity is a worldwide epidemic, negatively affecting every aspect of health. While treatment seems obvious: to limit energy intake, this approach appears largely unsuccessful. Testosterone plays an important role in male obesity. (Visceral) Adipose tissue is considered the largest endocrine organ producing a number of substances that suppress testosterone production. Low testosterone, however, leads to further accumulation of fat mass. This situation represents a vicious circle. Epidemiological studies consistently show that obesity is negatively associated with testosterone. Low testosterone is also associated with type 2 diabetes. Both for obesity and type 2 diabetes, the prevalence of testosterone deficiency (hypogonadism) can be as high as 50 per cent. Testosterone treatment in hypogonadal men has been consistently shown to decrease fat mass and simultaneously increase lean mass. This has been measured in numerous studies by using methodologies such as DEXA and MRI, confirming results from more simplistic measures such as BMI and waist circumference. The magnitude of body composition changes depends on the preparation used and the duration of treatment and can be an increase in lean mass of up to 4.8 kg and a decrease in fat mass of up to 5.4 kg. Recent long-term studies using testosterone in hypogonadal men have resulted in significant and sustained reductions in body weight and waist circumference. Weight loss was not only observed in a magnitude of more than 16 kg over 5 years, the reduction was also progressive and statistically significant compared to the previous year for the full observation period. Waist circumference declined by more than 8 cm in the same progressive fashion. There is increasing evidence that testosterone improves insulin sensitivity. Both controlled and long-term observational studies show a reduction in insulin, fasting glucose and HbA1c. While part of these effects are mediated by the changes in body composition, there also are direct effects of testosterone on insulin sensitivity. The mechanisms may involve mitochondrial function, regulation of GLUT4 and STAMP2 and others that are currently under investigation. In conclusion, testosterone may have the potential to reduce obesity and improve type 2 diabetes in hypogonadal men. These relevant insights are largely unknown to medical professionals and need to be confirmed by large-scale studies.

David Richard Matthews UK

Sulfonylureas: From Molecular Action to Clinical Benefits Insulin resistance and beta cell functional loss are both invariably present once type 2 diabetes is clinically apparent. There has been more than two decades of debate about the primacy of these pathophysiologies in the development of diabetes though no one now disputes their co-existence in the latter stages of the disease. This co-existence was the stimulus to find new agents that would reduce insulin resistance and new agents to stimulate beta-cell function. Both these approaches have been partially successful. The thiazolidinediones certainly reduced insulin resistance, though their side effects and some cautionary outcomes from trials and meta-analyses has caused a reappraisal of their use. Agents modulating insulin secretion have been generally more successful in clinical use. The first generation sulphonylureas tended to cause unwanted hypoglycaemia noted particularly in the UKPDS, which primarily used chlorpropamide and glibenclamide. Gliclazide, with a different molecular structure and duration of action emerged, in clinical practice, as an agent able to augment

3rd Emirates Diabetes & Endocrine Congress 2012

Abstracts both first and second phase insulin secretion with a low risk of hypoglycaemia. This was demonstrated in the ADVANCE trial where long-term therapy preferentially using a modified release gliclazide was associated with marked and significant reductions in renal microvascular pathology. The molecular binding capacity of different sulphonylureas is likely to be linked to their noted hypoglycaemia side effects: glibenclamide binds to two sites on the SUR receptor whereas gliclazide binds to only one. Glibenclamide â&#x20AC;&#x201C; in electrophysiological experiments â&#x20AC;&#x201C; binds irreversibly over many hours while gliclazide augments the normal physiology with a clearly notable off-time. Beta cell functional loss has been described using modelling techniques (HOMA) and hypoglycaemic clamp technology. Intravenous glucose infusions show early failure of first and second phase insulin secretion and even loss of subtle markers such as regular pulsatility. All these are reversible, to some extent, with gliclazide. The hunt is on to find agents that will slow or even reverse this functional loss; there is consensus that glibenclamide is associated with a higher rate of functional loss when compared with thiazolidinediones, but gliclazide seems to be associated with low rates of decline of beta-cell function. The therapeutics of insulin secretion have enlarged rapidly in the last decade. With a better understanding of the secretory mechanisms we are beginning to understand both the heterogeneity and the phenotypic variance of a variety of sub types of diabetes. Matching patients with optimal therapy is the emerging challenge.

Session IV Philip Schauer USA

Metabolic Consequences of Bariatric Surgery Submission Pending

Luc Van Gaal Belgium

Recent and Future Drugs for Obesity Submission Pending

Session V Alan J Garber USA

Early Glycemic Intervention and Long Term Outcomes The findings of the UKPDS published in 1998 transformed metformin from being a niche product for obese type 2 diabetic patients to what it has become today â&#x20AC;&#x201C; namely, the most widely used first line anti-diabetic agent in the world. In stark contrast to the disappointing failure of either insulin or sulfonylureas to improve CHD outcomes in patients with type 2 diabetes, metformin clearly reduced CHD events by 39%. This benefit remained evident even with the data of the 10 year follow-up study released in this Century. In the interim, most 38

3rd Emirates Diabetes & Endocrine Congress 2012

Abstracts endocrinologists assumed that other anti-diabetic therapies such as insulin and sulfonylureas would ultimately have a similar benefit in the 10 year extension. While all agents did produce a smaller 14% reduction over the 17 year average follow-up period, the metformin effect continued to be nearly 3 times large in terms of CHD event reduction. Independent studies designed to assess the effects of agents such as insulin, sulfonylureas or even good glycemic control all failed to show benefits with other agents. In ACCORD, intensive glycemic control increased rather than decreased total mortality, perhaps as the result of the lack of prespecified treatments and because of long lasting effects of hypoglycemia. On the other hand, sulfonylureas such as gliclazide failed to produce a macrovascular benefit even as it produced a microvascular benefit in the ADVANCE trial. Most recently, in the ORIGIN trial, early aggressive insulin therapy with a basal analog â&#x20AC;&#x201C; glargine â&#x20AC;&#x201C; also failed to produce any CHD benefit in more than 10,000 patients randomized to this therapy. Finally, we must conclude that few agents have substantial cardiovascular risk reduction when actually measured in randomized long term multi-center trials aside from metformin. Where possible, this agent should become the foundation of modern anti-diabetic therapies for most patients with type 2 diabetes.

Rainer Duesing Germany

Targeting Blood Pressure in Diabetic Patients Hypertension is an independent cardiovascular and renal risk factor with a substantial impact on morbidity and mortality. In the Global Burdon of Disease study, worldwide mortality in the year 2001 was analyzed with respect to underlying risk factors. In that study, between 7 and 8 million of the approximately 56 million fatalities could be attributed to arterial hypertension, supporting the notion that hypertension remains the most aggressive risk factor to date. However, it is important to note that the absolute risk associated with hypertension is largely dependent on comorbidities. In this context, diabetes is a key factor to dramatically increase the risk for cardiovascular and renal events in patients with hypertension. This is one of the reasons, why several guidelines have recommended goal blood pressure on treatment to be lower in hypertensive patients with comorbid diabetes. However, strong evidence for this recommendation is still lacking. Epidemiological data demonstrate that the prevalence of diabetes in hypertensive patients is approximately twice that in the general population. On the other hand, patients with diabetes exhibit high rates of hypertension ranging between 70â&#x20AC;&#x201C;90%. Among the underlying mechanisms of this prevalent comorbidity of hypertension and diabetes, overweight/ obesity has been identified to play a crucial role. The mechanisms of both obesity associated hypertension and diabetes have in part been elucidated. After manifestation of diabetes hypertension may also be promoted by renal functional changes due to diabetic nephropathy. Hypertension, on the other hand, may further impair insulin sensitivity by structural changes within the microcirculation. Prevention and therapy of overweight/obesity thus play a key role in cardiovascular and renal prevention.

Maximilian Von Eynatten USA

Diabetic Nephropathy: Is the Kidney the Unappreciated Heart in Type 2 Diabetes? Submission Pending

3rd Emirates Diabetes & Endocrine Congress 2012

Abstracts Session VI

Saturday, October 13, 2012 - Day 3

Rubina Heptulla USA

Diabetes in the Young Submission Pending

Donald Coustan USA

Gestational Diabetes Mellitus: Diagnosis and Management Submission Pending

Ralph Defronzo USA

New Concepts in Diabetes Pathophysiology: What We Should Know Submission Pending

Bernadette Biondi Italy

Clinical Significance of Subclinical Thyroid Dysfunction Submission Pending

3rd Emirates Diabetes & Endocrine Congress 2012

Workshop Abstracts MTP Sessions

Thursday, October 11, 2012 - Day 1

Margaret Wierman USA

Hyperprolactinemia and Pituitary Tumors Osteoporosis is a disorder of bone fragility that increases the risk for fracture. This lecture will review the incidence and prevalence of low bone mass in women and men and will outline the risk factors for fracture in patients. In addition to discussion of nonpharmacologic interventions and optimal calcium and vitamin D regimens, we will outline the currently available treatment strategies for osteoporosis including bisphosphonates, hormone therapy, recombinant parathyroid hormone and the monoclonal antibody against the RANK ligand. Efficacy and safety issues will be reviewed. New therapies in the pipeline will be outlined. Despite the morbidity and mortality associated with fracture, only limited numbers of patients are evaluated and treated, suggesting increased awareness and intervention are needed.

Om P. Ganda USA

Potential for Cardiovascular Benefits of Incretin Based Therapies Hyperglycemia, via a number of intermediary biochemical and metabolic pathways, leads to the incapacitating morbidity associated with micro-vascular and neuropathic complications. Moreover, in concert with other cardio-metabolic risk factors, hyperglycemia is a key underlying mediator of morbidity and mortality associated with cardiovascular disease. The tissue damage from hyperglycemia begins in the pre- diabetic phase. There is now evidence from several clinical trials that lifestyle changes aimed at weight management, and the pharmacological management of hyperglycemia and other CVD risk factors can help mitigate long- term complications of diabetes. Yet more than 50 % of patients are still not achieving glycemic, blood pressure, and lipid targets. During the past decade, several novel and emerging drugs have enabled us to achieve optimal glycemic control, generally in combination therapy, without untoward effects of weight gain, hypoglycemia, and other adverse effects with traditional agents. These include drugs related to the incretin hormones, and include the GLP1 receptor agonists, and the DPP-IV inhibitors. Their effect on islet alpha-cell function, leading to reduction in glucagon levels, in addition to improved insulin secretion in response to meals, provide a physiological approach to restoration of dual islet dysfunction in type 2 diabetes. The available GLP-1 receptor agonists are Exenatide and Liraglutide. The available DPP-4 inhibitors include Sitagliptin, Saxagliptin, Linagliptin, and Vildagliptin. Of these, Sitagliptin was the first to be launched in the US more than 6 years ago. These oral agents rovide excellent options in the pursuit of adherence to treatment, and have rapidly become a popular choice in combination with metformin, and/or other oral agents. The potential cardiovascular benefits of incretin-based drugs include lack of weight gain, modest improvement in blood pressure, lipids, and inflammatory markers. Since their availability, they have had a remarkable efficacy and safety record. Recent meta-analyses of short-term clinical trials with these agents have suggested a reduction in CVD endpoints of clinical significance. Currently, long- term trials to assess their cardiovascular safety and efficacy are underway.

3rd Emirates Diabetes & Endocrine Congress 2012

Workshop Abstracts Farid Saad Germany

Diagnosis and Treatment of Testosterone Deficiency Submission Pending

Anders Frid Sweden

Insulin Injection Techniques Insulin injection is the interface between drug and the body. If insulin absorption was similar from different injection sites and tissues the question of injection technique and needle length would not be very important. Understanding injection technique has to start with knowledge of insulin absorption. There are no rules that can be applied to all insulins so each type of insulin has to be evaluated separately. The following facts are known about insulin absorption:

Human insulins (soluble insulins, NPH-insulins) are absorbed more rapidly from the abdomen compared to thigh and also more rapidly from muscle compared to fat tissue. Rapid-acting insulin analogs (Humalog, NovoRapid, Apidra) have the same rate of absorption from abdomen compared to thigh. There is no difference in absorption from resting muscle compared to fat tissue. Long-acting insulin analogs (Lantus, Levemir) have a much more rapid absorption from muscle compared to thigh. Lantus has a slightly slower absorption from the abdomen compared to thigh while Levemir probably has a faster absorption from the abdomen (no published data).

Regarding fat tissue depth CT studies have shown that normal-weight patients, especially males, can have a very thin fat layer laterally in the thigh and laterally in the abdomen. Two studies show no differences in insulin absorption between superficial and deep fat layers. A recent study has shown that skin thickness is not greater than 3 mm with little variation with site, age and gender. The following rules can be suggested regarding injection technique:

There is no medical reason to use needles longer than 6 mm A 4 mm needle is sufficient in order to obtain a subcutaneous injection. When using a syringe the shortest available needle is 8 mm. Use a pinched skinfold when the fat tissue is thin. It is extremely important that long-acting insulin analogs are injected in the subcutaneous fat, I e with the correct technique.

From available scientific data it is obvious that the answer to the question in the title is a resounding YES!

3rd Emirates Diabetes & Endocrine Congress 2012

Workshop Abstracts MTP Sessions

Friday, October 12, 2012- Day 2

Rubina Heptulla USA

Introduction to Pediatric Endocrinology Submission Pending

Rainer Duesing Germany

Endocrine Hypertension In the presence of the high prevalence of arterial hypertension in the range of 30 % in the adult population, efforts for diagnosing secondary hypertension should be selective and restricted to settings with a high likelihood of such condition. In addition to renal causes endocrine disorders have emerged as common forms of secondary hypertension. Thus, primary aldosteronism, hyperthyroidism, Cushingâ&#x20AC;&#x2122;s syndrome and pheochromocytoma represent endocrine etiologies of hypertension. New clinical, biochemical, and radiologic approaches have significantly advanced our understanding of the clinical spectrum of these diseases and have also improved management strategies. Mineralocorticoid abnormalities and especially primary aldosteronism represent the most common form of endocrine hypertension. The detection of primary aldosteronism is of particular importance, since it provides an opportunity for a targeted treatment approach surgical for aldosterone producing adenoma (APA) and pharmacological with mineralocorticoid receptor antagonists for bilateral idiopathic adrenal hyperplasia (IAH)]. The diagnosis of primary aldosteronism is made following screening and confirmation/exclusion testing and, finally, subtype diagnosis (APA vs. IAH). Pheochromocytoma is a rare condition underlying secondary hypertension. However, because it is a dangerous and potentially even malignant condition, screening strategies should be employed in high-risk clinical settings. In the present review, the state of the art of strategies to diagnose and/or exclude endocrine hypertension will be described, highlighting new evidence and discuss issues that need to be addressed in the future.

Bernadette Biondi Italy

Replacement with Thyroid Hormone Submission Pending

Rayaz Malik USA

Diabetes Neuropathy and Diabetic Foot Submission Pending

3rd Emirates Diabetes & Endocrine Congress 2012

Workshop Abstracts Anders Frid Sweden

From available scientific data it is obvious that the answer to the question in the title is a resounding YES!

David Richard Matthews UK

Individualization of Diabetes Treatment Submission Pending

3rd Emirates Diabetes & Endocrine Congress 2012

Sponsors Main Sponsor

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world.

Platinum Sponsor

Lilly Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs. Additional information about Lilly is available at www.lilly.com. For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world’s first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy – practical tools, education, and support programmes to help overcome barriers to success along the diabetes journey. At Lilly, the journeys of each person living with or treating diabetes inspire ours. For more information, visit www.lillydiabetes.com.

3rd Emirates Diabetes & Endocrine Congress 2012

Sponsors

Novo Nordisk Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 30,000 employees in 79 countries, and markets its products in 179 countries. Novo Nordiskâ&#x20AC;&#x2122;s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange.

MSD MSD also known as Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA) is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, MSD discovers, develops, manufactures and vaccines & medicines to address unmet medical needs. Merck Sharp & Dohme (MSD) has been present for more than 35 years in the Gulf region. MSD Gulf operates through offices based in the capitals of UAE, Kuwait, Bahrain, Qatar & Oman and ranks amongst the leading pharmaceutical companies through the Gulf region. Through its local distributors, MSD Gulf provides innovative medication in several disease entities. These include products for Cardiovascular, Asthma, Pain & Inflammation, Osteoporosis, Neurological, & Ophthalmic Pathological Disorders, in addition to several specialized hospital product & vaccines.

3rd Emirates Diabetes & Endocrine Congress 2012

Sponsors

Sanofi Diabetes Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Gold Sponsor Servier Servier is the leading independent French pharmaceutical company. Established in 1954, Servier is a research-based pharmaceutical company dedicated to the discovery of new ethical drugs specializing in major diseases such as hypertension, cardiac diseases, diabetes, depression, venous disease and osteoporosis. The company has one of the world’s highest ratios of investment in R&D; an average of 25% of Servier’s turnover is invested in R&D.

Since its inception, Servier established and developed solid and productive partnerships that have made decisive contributions to the medical body and general community. Servier in the Gulf founded several partnerships with local and regional scientific bodies in the field of diabetes, osteoporosis, and cardiovascular diseases, contributing to their activities and supporting their initiatives in the aim of combating disease and improving quality of life of patients. As stated by Dr. Jacques Servier, founder of Les Laboratoires Servier “Trust is the cement of our partnerships, and it is based not simply on loyalty but also on long-term commitment”.

3rd Emirates Diabetes & Endocrine Congress 2012

Sponsors

Merck Serono Merck Serono is the biopharmaceutical division of Merck KGaA. With headquarters in Geneva, Switzerland, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono. Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurodegenerative diseases, oncology and rheumatology. For more information, please visit www.merckserono.com or www.merckgroup.com

BMS Bristol-Myers Squibb and AstraZeneca entered into collaboration in January 2007 to enable the companies to research, develop and commercialise two investigational drugs for type 2 diabetes The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes.

Silver Sponsor LifeScan Likewise, Lifescan (www.lifescan.com) is committed to improving the quality of life for people with diabetes. As a world leader in blood glucose monitoring for both home and hospital use, LFS introduced a Technology that made testing less painful and proved to be accurate and convenient, and is continuously working to bring the next important advances in diabetes care.

3rd Emirates Diabetes & Endocrine Congress 2012

Sponsors

MPC Modern Pharmaceutical Company (www.modernpharma.ae) is an active partner in the advancement of healthcare in the UAE. It has remained the distributor of choice by having a single objective: Excellence in the products and services we provide:

Medtronic The Diabetes business at Medtronic (www.pumpersclub.com) is the world leader in advanced diabetes management solutions, including insulin pump therapy, continuous glucose monitoring systems and therapy management software, as well as world-class, 24/7 expert consumer and professional service and support. Medtronic is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

AMGEN Bronze Sponsor Julphar Diabetes Julphar Diabetes is the division of Julphar that manages the manufacturing and commercialization of diabetes products which include oral anti-diabetics and insulin Julphar has made an important strategic decision to become one of the Middle Eastâ&#x20AC;&#x2122;s leaders in offering world class treatment for both Type 1 and Type2 diabetes. Among the key regional providers of diabetes management, Julphar Diabetes is the only company to offer a comprehensive portfolio of high quality , affordable products that doctors and patients continue to endorse. Our Vision: Establish Julphar Diabetes as the cornerstone for achieving A1C goals in all diabetic Patients in MEAA Our Mission: Reduce the burden of Diabetes to Patients and Health Care Providers through a portfolio of high quality, accessible products.

3rd Emirates Diabetes & Endocrine Congress 2012

Sponsors

BD BD is a leading global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers,

clinical

laboratories,

the

pharmaceutical

industry

and

the

general

public.

Boehringer Ingelheim and Lilly The Diabetes Alliance In January 2011 the Boehringer Ingelheim & Lilly Diabetes Alliance was announced. It will leverage the Collective scientific expertise & business capabilities of two leading research-driven pharmaceutical companies to address patient needs arising from the growing global diabetes epidemic Value through Innovation” A research-driven company dedicated to researching and developing, manufacturing and marketing pharmaceuticals that improve health and quality of life Founded in 1885 Headquartered in Ingelheim (Germany) ~ 42,000 employees worldwide (2010) “Answers that Matter” A leading innovation-driven corporation providing answers – through medicines and information – for some of the world’s most urgent medical needs Founded in 1876 Headquartered in Indianapolis, Indiana (USA) ~ 39,000 employees worldwide (2010) Our joint Alliance Mission Inspired to deliver innovative solutions That makes a difference for people affected by diabetes

3rd Emirates Diabetes & Endocrine Congress 2012

Sponsors Support Sponsors Cleveland Clinic Cleveland Clinic, a not-for-profit multispecialty academic medical center based in Cleveland, Ohio, USA, was founded in 1921 by four renowned physicians who envisioned an ideal medical practice involving collaboration among specialists from many fields. Through this group practice, they sought to provide exceptional patient care while pursuing research and educating healthcare providers. Today, the nearly 3,000 staff physicians and scientists in 120 specialties and subspecialties collaborate to give every patient the best outcome and experience. Cleveland Clinic is ranked among America’s top hospitals overall, and among the nation’s leaders in every major medical specialty according to U.S. News & World Report. Cleveland Clinic physicians’ commitment to collaboration extends to colleagues across the global medical community. Our presence in facilities ranging from Nevada to Florida in the United States, and from Canada to Abu Dhabi in the United Arab Emirates internationally makes that easier than ever before. Link the logo to: www.clevelandclinic.org

Bayer Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. As an inventor company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal 2011, the Group employed about 112,000 people and had sales of €36.5 billion. Capital expenditures amounted to €1.7 billion, R&D expenses to €2.9 billion. For more information, go to www.bayer.com.

3rd Emirates Diabetes & Endocrine Congress 2012

Sponsors

HIKMA Hikma Pharmaceuticals is a fast growing multinational group which was founded in 1978. It is listed in the London Stock Exchange and in NASDAQ Dubai. It is focused on developing, manufacturing and marketing a broad range of branded and non branded generic and in-licensed products. Hikma’s operations are conducted through three businesses: “Branded”, “Injectables” and “Generics” based principally in the Middle East and North Africa region, where it is a market leader, the United States and Europe, and has numerous multinational partners. Hikma is committed to the highest quality manufacturing with multiple FDA approved facilities.

3rd Emirates Diabetes & Endocrine Congress 2012

Experience Dubai

About Dubai Dubai - the exotic j jewel of the United Arab Emirates; Bordered by deserts

and beaches, Dubai provides stark contrasts, from intriguing Islamic culture to the ultra-modern, high-tech metropolis of the 21st century. The city is a magnificent expression of an incredible vision and an uncompromising statement of success and opportunity. Dubai has something for everyone, from vacationers seeking a relaxing break away from the pressures of work, to business travellers looking for a new exciting experience. The emirate is an international conference, exhibition and leisure destination. Lying on the calm, blue waters of the southern Gulf and flanked by the majestic desert, Dubai offers year-round sunshine and five-star luxury along with the adventure of a unique Arabian experience. Dubai is a class destination with all the modern amenities of the western world. It is a fascinating emirate with beautiful buildings, excellent restaurants and nightlife as well as white sandy beaches, culture and history that you can feel as you visit the souks, shopping malls, museums and historic buildings and sites.

Climate Dubai has a sub-tropical, arid climate. Sunny, blue skies can be expected most of the year. Rainfall is infrequent and irregular, falling mainly in winter. Temperatures range from a low of about 10.5°C /50 °F to a high of 48°C/118.4°F. The mean daily maximum is 24 °C/75.2 °F in January rising to 41°C/105.8 °F in July.

Clothing Lightweight summer clothing is suitable for most of the year, but sweaters or jackets may be needed for the winter months, especially in the evenings. Compared with certain parts of the Middle East, Dubai has a very relaxed dress code. However, care should be taken not to give offence by wearing clothing which may be considered revealing, for example low-cut dresses, very short skirts, or tight shirt or top in public. At the pool or on the beaches, trunks, swimsuits and bikinis are quite acceptable. Good quality sunglasses are advised, and photo chromatic lenses for those who wear spectacles. Hats, or some protection for the head, are advisable when in direct sunlight. 3rd Emirates Diabetes & Endocrine Congress 2012

Experience Dubai

Culture & Lifestyle Dubaiâ&#x20AC;&#x2122;s culture is firmly rooted in the Islamic traditions of Arabia. Courtesy and hospitality are among the most highly prized of virtues, and the visitor is sure to be charmed by the genuine warmth and friendliness of the people. Dubai society is marked by a high degree of tolerance for different lifestyles. Foreigners are free to practice their own religion, alcohol is served in hotels and, provided reasonable discretion is shown, the dress code is liberal. Women face no discrimination and may drive and walk around unescorted. Despite rapid economic development in recent years, Dubai remains close to its heritage. Local citizens dress in traditional robes and headdress. Arab culture and folklore find expression in poetry, dancing, songs and traditional art. Weddings and other celebrations are colourful occasions of feasting and music. Traditional sports such as falconry, camel racing and dhow racing at sea continue to thrive.

Language & Religion The official language is Arabic but English is widely spoken and understood. Both languages are commonly used in business and commerce. Islam is the official religion of the UAE and there are a large number of mosques throughout the city. Other religions are respected and Dubai has two Christian churches, St Maryâ&#x20AC;&#x2122;s (Roman Catholic) and Holy Trinity (inter-denominational).

Photography Normal tourist photography is allowed, however it is considered offensive to photograph Muslim women. It is also courteous to request permission before photographing men.

Currency The

monetary unit is the dirham which is divided into 100 fils. The dirham is linked to the Special Drawing Right of the International Monetary Fund. It has been held constant against the US dollar since the end of 1980 at a mid-rate of approximately US$1= Dh3.67. 54

3rd Emirates Diabetes & Endocrine Congress 2012

Experience Dubai Dubai City Tour ‘Taste of Dubai’ Pass by Jumeirah Mosque, which is a spectacular example of modern Islamic architecture and is one of the most photographed sights in Dubai. Drive past impressive Beach Palaces of Dubai Sheiks. Visit the museum which throws light on Dubai’s historical links with trading and pearl diving. Enroute we also pass by the ancient, beautifully restored house of Sheikh Saeed, the grandfather of the present Ruler of Dubai. The housed in the 180 year old Al FahidiFort, and Bastakia region which has wind towered houses, that is still standing as a reminder of the grace-full and resourceful architecture that predated the arrival of electricity and air-conditioning.

Dhow Cruise Discover the true beauty of Dubai while aboard of a traditionally decorated wooden dhow as it sails along the Dubai creek under the moonlight. It offers an intriguingly different view of the beautiful city Dubai, which is a delightful mix and match of the traditional and modern way of life. The majority of the Dubai landmarks can be viewed while on board of the dhow, splendid examples of modern architecture like the National Bank of Dubai and the spectacular Chamber of Commerce and Industry building, whilst Sheikh Saeed’s House, the birthplace of Sheikh Rashid and the Heritage Village are reminiscent of days gone by. This evening cruise includes a buffet dinner, along with soft drinks, coffee and mineral water.

3rd Emirates Diabetes & Endocrine Congress 2012

Experience Dubai Modern “Do Buy” Shopping Tour Dubai is a shopper’s paradise offering an endless choice to suit every budget. We’ll take you shopping to multi-level, world-class, air-conditioned malls where you get the latest of everything the world has to offer. Our shopping tour will take you to the following places. Souk Madinat Jumeirah - The souk is a colorful and vibrant market or part of a market in an Arabian city. Lively trading culture, animated, interactive - this defines Souk MadinatJumeirah. Dubai Mall - Is the region’s premier shopping, lifestyle and entertainment destination. With more than 1,200 stores and a host of world-class attractions, The Dubai Mall is revolutionizing the modern shopping experience. With an impressive array of leisure pursuits, this is the ultimate, cutting-edge shopping experience. A range of adventure sports vies for attention alongside the romance of ice-skating. The Dubai Mall is a place where outdoor brunch can be followed by the delights of the big screen and where a 21st century gold souk is set off against a world class Aquarium. When was the last time your sortie to the designer stores took place under the watchful eye of a giant sea turtle? Step inside The Dubai Mall and experience a place like no other. Desert Safari BBQ Dinner This tour departs in the afternoon by 4WDs across the desert of Dubai with several photo-stops during an exciting dune drive to the first destination, a camel farm. The drive continues across the desert. We stop to watch the beautiful sunset before reaching our campsite where you have the opportunity to do a camel ride, sand boarding and try out a henna design on hand or feet. Enjoy a delicious barbecue dinner and shisha (the famous Arabic water pipe). Before returning to Dubai watch our belly dancer performing her show around the campfire by starlight. This tour Includes 40 min dune drive, BBQ dinner, belly dancing, henna tattoo, camel ride, hubbly bubbly, soft drink and mineral water.

3rd Emirates Diabetes & Endocrine Congress 2012

Acknowledgement Main Sponsor

Platinum Sponsors

Gold Sponsors

Silver Sponsors

Bronze Sponsors

Support Sponsors

Exhibitors Bayer Diabetes

Pfizer

Delma Al Redwan Official News Distributor

PIC Solution

Abbott Diabetes Media Partners

3rd Emirates Diabetes & Endocrine Congress 2012

Thank You for Your Support

Congress Secretariat: MCI Middle East Tel: +971 4 311 6300, Fax: +971 4 311 6301, E-mail: edec@mci-group.com 58

3rd Emirates Diabetes & Endocrine Congress 2012